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Abstract
Background: Hib vaccine has gradually been introduced into more and more countries during the past two decades, partly
due to GAVI Alliance support to low-income countries. However, since Hib disease burden is difficult to establish in settings
with limited diagnostic capacities and since the vaccine continues to be relatively expensive, some Governments remain
doubtful about its value leading to concerns about financial sustainability. Similarly, several middle-income countries have
not introduced the vaccine. The aim of this study is to estimate and compare the cost-effectiveness of Hib vaccination in a
country relying on self-financing (Belarus) and a country eligible for GAVI Alliance support (Uzbekistan).
Methods and Findings: A decision analytic model was used to estimate morbidity and mortality from Hib meningitis, Hib
pneumonia and other types of Hib disease with and without the vaccine. Treatment costs were attached to each disease
event. Data on disease incidence, case fatality ratios and costs were primarily determined from national sources. For the
Belarus 2009 birth cohort, Hib vaccine is estimated to prevent 467 invasive disease cases, 4 cases of meningitis sequelae,
and 3 deaths, while in Uzbekistan 3,069 invasive cases, 34 sequelae cases and 341 deaths are prevented. Estimated costs per
discounted DALY averted are US$ 9,323 in Belarus and US$ 267 in Uzbekistan.
Conclusion: The primary reason why the cost-effectiveness values are more favourable in Uzbekistan than in Belarus is that
relatively more deaths are averted in Uzbekistan due to higher baseline mortality burden. Two other explanations are that
the vaccine price is lower in Uzbekistan and that Uzbekistan uses a three dose schedule compared to four doses in Belarus.
However, when seen in the context of the relative ability to pay for public health, the vaccine can be considered cost-
effective in both countries.
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Introduction
Haemophilus influenzae type b (Hib) is an encapsulated, Gram-
negative coccobacillus that can cause meningitis, pneumonia and a
number of rarer forms of disease, such as epiglottitis, septicaemia and
cellulitis, primarily in children less than five years [1]. Survivors of
Hib meningitis risk severe lifelong disabilities, such as deafness and
neurological disorders [2]. A Hib conjugate vaccine has been
available since the early 1990s and has led to virtual elimination of the
disease in countries with sustained high vaccination coverage [3,4].
In Eastern Europe and Central Asia, Hib vaccine uptake has
been slow, primarily due to uncertainty about Hib disease burden
and because the vaccine is considerably more expensive than
traditional childhood vaccines [5]. For the nine poorest countries in
the regions, including Uzbekistan, Hib vaccine introduction has
been facilitated by funding from the GAVI Alliance. The other eight
European and Central Asian countries that have received Hib
vaccine from the GAVI Alliance are Albania, Armenia, Azerbaijan,
Bosnia & Herzegovina, Georgia, Moldova, Kyrgyzstan and
Tajikistan. The support to Uzbekistan began in March 2009 and
is scheduled to end in 2015, at which point the Government needs
to decide whether it wants to continue using the vaccine and if so,
how it will be financed. In Belarus, Hib vaccination was started by
the local Government of Minsk city in 2008 covering around one-
fifth of the birth cohort. The national Government is currently
considering whether to expand it to the rest of the country.
The aim of this study is to estimate and compare the cost-
effectiveness of Hib vaccination in a country relying on self-
financing (Belarus) and in a country eligible for GAVI Alliance
support (Uzbekistan). The Governments of both countries
requested the analyses from the WHO with the purpose of using
the evidence to guide their decision making on the vaccine.
Methods
Hib disease definitions
Hib disease was categorised as pneumonia, meningitis, and
‘‘non-pneumonia-non-meningitis’’ (NPNM), replicating groupings
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used by the Global Burden of Hib and Pneumococcal disease
project [6,7]. Pneumonia was defined as any case of pneumonia
recorded by the Ministry of Health surveillance databases in
Uzbekistan and Belarus, regardless of radiological confirmation.
Meningitis was defined as any case of inpatient hospital meningitis.
NPNM included other specific diseases in children that can be
caused by the Hib bacterium, such as cellulitis, osteo myelitis,
septic arthritis and epiglottitis.
Decision analytic model structure
A static, compartmental cohort model was used to estimate Hib
disease events for children of the 2009 birth cohorts in the two
countries. The model is illustrated in Figure 1. Projected numbers
of person-years lived between 1 and 59 months were multiplied by
disease incidence rates to estimate Hib cases in each cohort. An
all-cause pneumonia incidence rate was used to calculate total
pneumonia cases and it was assumed that a proportion of these
were caused by Hib. Hib meningitis and Hib NPNM cases were
calculated directly from aetiology specific incidence rates. A
proportion of cases were assumed to seek health care and each of
these incurred an average treatment cost. Hib deaths were
estimated from case fatality ratios (CFRs) and a risk of permanent
disability was applied to all survivors of Hib meningitis and
classified according to type.
The impact of Hib vaccine was estimated as the difference
between scenarios with and without the vaccine. In the vaccine
scenario, numbers of cases were reduced by dose-specific
vaccination coverage and dose-specific vaccine efficacy. Incre-
mental cost-effectiveness ratios (ICERs) were calculated by
dividing the difference in expected costs between the two scenarios
with the difference in expected health effects, expressed as cases,
deaths and lost Disability Adjusted Life Years (DALYs). The
analysis was undertaken from a societal perspective; including
costs incurred by the Governments, the GAVI Alliance and
households. While the Government health sector is dominant in
both countries with very limited private health services available, it
is common practice in Uzbekistan that patients pay a proportion
of drug costs when accessing public services and these were
included in the analysis. Transport and time costs were excluded
as we did not conduct patient interviews as part of the study.
Future costs and effects were discounted by 3% per year [8].
Treatment costs were estimated in 2009 US$ using exchange rates
of 2,793 Belarusian rubles and 1,464 Uzbek som to one US$. The
model was developed in Microsoft Excel. Model input parameter
values are summarised in Table 1 and justifications for these given
below.
Health care utilization
As seen in Figure 1, CFRs are assumed to vary with health care
utilisation, implying that the risk of death is higher if no formal
health care services are accessed. Similarly, when incidence rate
calculations are based on data from hospital surveillance only, it is
necessary to adjust these as cases would inevitably be missed in
settings with limited access to care. In Uzbekistan, a 2006 Multiple
Indicator Cluster Survey reported that of children aged 0–59
months with pneumonia symptoms during the two weeks
preceding the survey, only 68% were taken to an appropriate
provider [9]. We used this figure to adjust CFRs and hospital
disease incidence rates for all types if Hib disease.
Balabanova et al. illustrated that Belarus has the highest health
service utilization out of eight former Soviet Union countries[10],
and the country also has the largest number of doctors and nurses
per 1,000 population within central- and Eastern Europe [11]. In
particular, children’s health is monitored closely with general
check-ups by all main specialists annually until 18 years of age
[11]. Therefore, we did not adjust hospital incidence rates and
CFRs for limited access to care in Belarus.
Hib disease incidence parameters
Hib meningitis. Meningitis is the most studied type of Hib
disease for three key reasons: it is the most severe form of Hib
disease, it has a relatively straightforward clinical diagnosis, and it
is the type of Hib disease that can be most easily diagnosed in a
laboratory (from cerebrospinal fluid (CSF) of patients with clinical
symptoms). Hence, when assessing Hib disease burden, meningitis
is often the preferred starting point.
In Belarus, population-based childhood bacterial meningitis
surveillance was in place at Minsk City Children’s Infectious
Disease Hospital (MCCIDH) during 2002–2007 [12,13]. During
the six-year period, 175 purulent meningitis cases were detected in
children , 5 years and a bacterial pathogen was identified for 87
of these, giving an average bacterial meningitis incidence rate of
31 per 100,000 children , 5 years (Table 2). 30 of the cases were
confirmed as Hib, generating an incidence of 5 per 100,000
children, with annual rates between 1 and 10. However, since 88
of the purulent cases had no confirmed pathogen, this is likely to
be an underestimate of the true number. According to WHO
guidelines [14] and following methods used in other bacterial
meningitis aetiology studies [15], culture negative cases should be
allocated to bacterial pathogens according to their proportion of
confirmed cases. Hence, we apportioned 34% of the non-
confirmed cases to Hib and estimated an adjusted Hib meningitis
incidence rate of 10.8 per 100,000 children , 5 years, with a
range between 7.4 and 15.1.
Since no population based meningitis surveillance studies have
been conducted in Uzbekistan, we used routine surveillance data
for our estimates. 234 hospitals reported 5,245 clinical meningitis
cases in children , 5 years in 2007, giving an incidence of 166 per
100,000 children. We adjusted this estimate upwards by 32% to
account for limited access to care, arriving at 219 per 100,000
children. The proportion of meningitis caused by Hib was
approximated from a study conducted by the Uzbek Ministry of
Health and the US Naval Medical Research Unit no. 3 in
Egypt[16]. 165 CSF samples from children with clinical meningitis
admitted to hospitals in Tashkent and Samarkand during 2002–
2004 were tested using Polymerase Chain Reaction and 61 were
found to be purulent with nine of them confirmed as Hib[16]. The
adjusted number is thus 14 cases, equivalent to 8.5% of all the cases
tested. We therefore estimated a Hib meningitis incidence of 18.7
per 100,000 children , 5 years (8.5% of 219).
For comparison, the Hib Global Burden of Disease (GBD)
project estimated a Hib meningitis incidence rate of 16 per 100,000
children, 5 years for the WHOEuropean region [6]. We used this
estimate for in both countries in the sensitivity analyses.
Hib pneumonia. All-cause pneumonia incidences were
determined from routine surveillance systems in both countries.
In Belarus, 10,402 pneumonia cases in children less than five years
were reported during 2008, giving an annual incidence of 2,302
per 100,000 children, based on an under-five population of
451,960[17]. 84% of cases were reported from hospitals and the
remaining from outpatient clinics. In Uzbekistan, 20,014
pneumonia cases were reported in 2007, giving an incidence of
633 per 100,000 children , 5 years (under-five population is
3,162,151)[17]. 230,201 acute respiratory infections (ARI) cases
were reported the same year, 15% of which were hospitalised.
When hospitalised ARI cases are included, the incidence rate
increases to 1,724 per 100,000. After adjusting for limited access to
care, the incidence is 2,277 per 100,000 children , 5 years.
Economic Evaluation of Hib Vaccination
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Since the signs and symptoms of Hib pneumonia cannot be
differentiated from those of pneumonia caused by other
microorganisms, the incidence of Hib pneumonia can best be
approximated from Hib vaccine trials[18]. Meta-analysis of Hib
vaccine trials in the Gambia and Indonesia showed that Hib
causes approximately 5% (95% CI 3%–14%) of clinical pneumo-
nia [6,7]. This corresponds to Hib pneumonia incidences of 115
and 114 per 100,000 children , 5 years in Belarus and
Uzbekistan, respectively. These rates are approximately half of
the numbers reported by the GBD project, which estimated an
average Hib pneumonia incidence in the WHO European region
of 283 per 100,000 children , 5 years in the absence of Hib
vaccine (range 259–463) [6]. This estimate is used in sensitivity
analyses.
Hib NPNM. There are no data on Hib NPNM diseases in
Belarus and Uzbekistan. Studies from Bulgaria and Czech
Republic assessing all types of Hib diseases reported an average
of 0.57 NPNM cases for each meningitis case [19,20]. The most
important type was epiglottitis, accounting for 78% of cases. We
thus assumed a Hib NPNM incidence of 6.15 and 10.65 per
100,000 children , 5 years in Belarus and Uzbekistan,
respectively (Table 1). The GBD project estimated a Hib
NPNM incidence rate of 5.0 per 100,000 children , 5 years for
the WHO European region [6].
Case fatality ratios
In the Minsk city meningitis surveillance project, one of the 30
children with confirmed Hib meningitis died, giving a case fatality
ratio of 3.2%. This is comparable to CFRs reported in Western
European countries, such as 5% in the United Kingdom [21] and
4% in France [22]. Only six and five pneumonia deaths in
children , 5 years were reported in Belarus during 2007 and
2008, respectively. This is equivalent to around 2% of all deaths in
children and a CFR of 0.3% for all-cause pneumonia.
In Uzbekistan, 22 children, 5 years were reported to have died
from meningitis in 2007, giving a CFR of 0.42%. For Hib
meningitis, this figure is however unrealistically low. We used data
from an Indian study reporting a hospital CFR of 15% [23] and
assumed a CFR of 100% for the 32% of children that do not reach
formal health care [24]. The overall CFR was thus 42%.
According to Uzbek hospital surveillance data, a total of 214
pneumonia deaths occurred in 2007, generating all-cause hospital
pneumonia CFR of 1.07%. We assumed 10% CFR for those
without access to care, giving a weighted mean of 4%. NPNM
CFRs were assumed similar to those of meningitis for the 78%
epiglottitis proportion and zero for the other NPNM diseases
(Table 1).
The GBD project estimated CFRs in the WHO European
region of 5%, 27% and 1% for Hib pneumonia, meningitis and
NPNM, respectively [6]. These estimates are averages of a very
diverse region in terms of income and access to health services.
Albeit these estimates are very different than ours, we included
them in the sensitivity analyses to illustrate the impact a change in
CFRs has on the result.
Meningitis sequelae
In Belarus, all children that have suffered from meningitis are
followed up every three months during the first year after
Table 1. Parameter values used in the base-case analysis.
Parameter name Belarus Uzbekistan
Sources
Belarus/Uzbekistan
2009 live births 96,337 558,459 [17]
2009 life expectancy at birth (years) 69 68 [17]
2009 vaccine coverage of third DTP dose 96% 98% [30]
Incidence per 100,000 children , 5 yrs:
All-cause clinical pneumonia 2,302 2,277 Belarus/Uzbek MOH
Hib NPNM 6.15 10.65 [19,20]
Hib meningitis 10.1 18.7 [12,13]/[16]
Proportion of clinical pneumonia due to Hib 5% 5% [7]
Proportion of meningitis cases with disability 12% 14.5% Minsk City surveillance/[2]
Case fatality ratios:
Hib pneumonia w/o access to care NA 10% NA/Assumption
Hib pneumonia with access to care 0.3% 1.07% MOHs routine surveillance
Hib NPNM w/o access to care NA 78% NA/Assumption
Hib NPNM with access to care 2.5% 12% Assumptions
Hib meningitis w/o access to care NA 100% NA/Assumption
Hib meningitis with access to care 3.2% 15% [13]/[23]
Treatment utilization
Percent of pneumonia cases seeking care 100% 68% [10]/[9]
Percent of NPNM cases seeking care 100% 68% [10]/[9]
Percent of meningitis cases seeking care 100% 68% [10]/[9]
doi:10.1371/journal.pone.0021472.t001
Figure 1. Hib disease model structure.
doi:10.1371/journal.pone.0021472.g001
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discharge and annually for the next two years. Data from
MCCIDH revealed that 12% of children with confirmed Hib
meningitis suffered from disability at six months follow-up; 75% of
these had reduced hearing. Due to lack of data in Uzbekistan we
used a global meta-analysis estimate of 14.5% of all Hib meningitis
survivors suffering from sequelae [2].
Disability adjusted life years
The standard DALY formula and disability weights of 0.28 and
0.616 for pneumonia and meningitis, respectively, were used [25].
As there are no disability weights available for any of the NPNM
diseases, the meningitis weight was used as an approximation, as
epiglottitis has comparable severity to meningitis. The duration of
episode was assumed similar to the average length of stay in
hospital for all acute illnesses and life-long for meningitis sequelae.
Proportions of the eight different types of sequelae were as follows
[2], with the respective disability weights in parentheses [25]:
Cognitive difficulties 7.6% (0.0777), seizure disorders 10.4%
(0.0987), hearing loss 22.2% (0.2331), motor deficit 15.3%
(0.3884), visual disturbance 3.5% (0.6), behavioural problems
14.6% (0.0777), clinical impairments 8.3% (0.4687), and multiple
disabilities 18.1%. A weighted disability weight of 0.8571 was
calculated for multiple impairments.
Treatment costs
Data on drug usage and average length of stay in hospital were
collected from a review of patient records at selected health
facilities in both countries. Costs of drugs were collected from
hospital pharmacies and the costs per hospital bed-day were
provided by hospital administrators. In Belarus, meningitis
treatment costs were collected at MCCIDH and pneumonia costs
from Minsk Regional Hospital and Stolbtsy District Hospital. In
Uzbekistan, treatment costs of meningitis were collected at the
Infectious Disease Hospital #1 and pneumonia data at the
Paediatrics Research Institute, the Children’s Hospital #5 of
Yunusobod District, and the Uchtepa District Children’s Hospital.
Household costs for drugs were approximated by assuming that
prescribed drugs were purchased in local pharmacies. Discounted
lifetime treatment costs of meningitis sequelae were approximated
from a Russian study as US$ 32,660 for both countries [26].
In Belarus, the average length of stay in hospital was 21 days per
meningitis episode and between 12 and 14 days for pneumonia. In
this country it is required that children who have suffered from
meningitis should be re-hospitalised for follow-up one month and
again six months after the initial discharge. Out of 18 meningitis
cases at MCCIDH, two were re-admitted three times, seven two
times and nine one time as part of their follow-up. We thus
assumed that all children with meningitis were re-hospitalised 1.6
times with an average length of stay of 9 days. We further assumed
three outpatient visits per pneumonia and NPNM episodes and
seven visits per meningitis episode [11]. In Uzbekistan, the average
length of stay in hospital was 11 days for meningitis and there is no
policy for re-admission. The average length of stay for pneumonia
was nine days and we assumed two outpatient visits for each Hib
disease hospital admission. Costs of outpatient visits were based on
WHO estimates; US$ 9.21 per visit in Belarus and US$ 1.53 per
visit in Uzbekistan [27].
Hib vaccine assumptions
In Belarus, a ministerial order dictates a four-dose Hib vaccine
schedule, following a WHO recommendation of a booster dose in
countries where Hib disease frequently occurs in children above 18
months of age [28]. In Minsk City, the schedule is 3, 4, 5 and 18
months, and the combined diphtheria-tetanus-pertussis (DTP)-Hib
vaccine is procured from Sanofi Pasteur at US$ 4.95 per dose. We
assumed a similar price for the national analysis. In Uzbekistan,
three doses of combined DTP-hepatitis B-Hib vaccine are given at 2,
3 and 4 months. In 2010 Unicef procured the vaccine for the GAVI
Alliance at a price per dose of US$ 3.00[29]. Since both countries use
a single dose vial, vaccine wastage is only estimated as 5%.
We interviewed vaccine programme staff to assess any logistical
costs related to introducing the vaccine. It was revealed that even
though vaccine volume had increased, existing cold chain
capacities were sufficient in both countries with no additional
investments required. In Uzbekistan, a GAVI introduction grant
of US$ 100,000 was used for staff training and this cost was
included in the analysis.
Vaccination coverage data reported by WHO and Unicef were
used[30]. Hib vaccine efficacy was assumed as 86% after three
doses [31], 81% after two doses [32] and 51% after one dose [32].
Sensitivity analysis
To illustrate the impact of changes in incidence estimates and
CFRs, the primary sensitivity analysis was a scenario using the
Table 2. Reported purulent* meningitis cases in children less than 5 years in Minsk city, Belarus.
Year
Number of
confirmed
Neisseria
meningitis cases
Number of
confirmed Hib
cases
Number of confirmed
Streptococcus
pneumoniae cases
Number of
confirmed other
bacteria
Number of
culture
negative cases
Number of
purulent
cases*
Bacterial meningitis
incidence per 100,000
children , 5 years**
2002 3 2 1 0 12 18 24.94
2003 7 6 1 0 11 25 33.57
2004 10 5 1 0 12 28 36.54
2005 9 7 3 0 14 33 42.13
2006 7 1 3 1 25 37 45.69
2007 6 5 1 1 6 19 22.27
2008 3 4 0 0 8 15 16.37
TOTAL 45 30 10 2 88 175 31.28
*Purulent meningitis is defined as visibly turbid or cloudy OR WCC . 100.
**Incidence rates are calculated from the following under-five population in Minsk city: 2002: 72,168, 2003: 74,469, 2004: 76,623, 2005: 78,323, 2006: 80,985, 2007:
85,335, 2008: 91,623.
doi:10.1371/journal.pone.0021472.t002
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WHO European region GBD numbers for both countries; thus
assuming that the epidemiological parameters are similar in the
two settings. Univariate sensitivity analyses were also done by
assuming 100% access to care in Uzbekistan, a Hib vaccine price
of US$ 2 per dose and no discounting of future values.
Furthermore, since the decision-analytic model is static, indirect
effects from lower risk of exposure in unvaccinated children,
commonly referred to as ‘‘herd immunity’’, are not directly
incorporated[33]. To evaluate the potential importance of herd
effects, we multiplied the direct vaccine impact by 20% in a
scenario analysis [34].
Results
Disease impacts
For Belarus, it was estimated that the vaccine prevents 493 Hib
disease cases and three deaths each year, while in Uzbekistan
3,072 cases and 341 deaths are averted annually. Four and 34
cases of meningitis sequelae are also prevented each year in
Belarus and Uzbekistan, respectively. The results in discounted
form are shown in Table 3. Deaths averted represent approxi-
mately 0.3% and 1.1% of total 2009 under-five mortality in
Belarus and Uzbekistan, respectively.
Treatment costs averted
In Belarus, the average costs per bed-day excluding patient-
specific costs, such as drugs and meals, were US$ 40 at MCCIDH
and US$ 23 at Stolbtsy District Hospital. When multiplying by
average length of stay and including patient-specific items, average
meningitis treatment costs amounted to US$ 1,311 per acute
episode and average pneumonia costs to US$ 413, US$ 448 and
US$ 542 for district, regional and MCCIDH levels, respectively.
In Uzbekistan, costs per hospital bed-day were estimated as US$
9.10. Average costs of treating meningitis amounted to US$ 238,
US$ 257 and US$ 276 at district, regional and national hospital
levels, respectively, and the cost per pneumonia patient was
estimated as US$ 268 for all levels. Annual treatment costs with
and without Hib vaccine are summarised in Table 3. In
Uzbekistan, approximately 27% of the costs are covered by
households as out-of-pocket payments for drugs.
Incremental vaccine delivery costs
Without Hib vaccine, costs of vaccines and syringes per fully
vaccinated child amounted to approximately US$ 23 in Belarus
and US$ 8 in Uzbekistan (Table 4). Introduction of Hib vaccine
increases annual costs by 84% in Belarus and 101% in Uzbekistan,
leading to costs per fully vaccinated child of US$ 43 and US$ 16,
respectively.
Cost-effectiveness
Costs per discounted DALY averted amount to US$ 9,323 in
Belarus and US$ 267 in Uzbekistan (Table 5). Since life years
gained represent as much as 66% and 97% of incremental DALYs
in Belarus and Uzbekistan, respectively, discounting makes a
considerable difference to the ICER. Without discounting, the
results are US$ 3,573 in Belarus and US$ 77 in Uzbekistan. When
using the Uzbekistan GAVI co-financing amount of US$ 0.30 per
dose instead of the vaccine price, Hib vaccine is cost saving for the
Table 3. Estimated Hib disease and treatment costs in Belarus and Uzbekistan with and without Hib vaccine for the 2009 birth
cohorts.
Belarus Uzbekistan
No vaccine Vaccine Prevented No vaccine Vaccine Prevented
Cases:
Hib pneumonia 504 95 409 2,994 608 2,387
Hib meningitis 44 8 36 492 100 392
Hib NPNM 27 5 22 280 57 223
Meningitis sequelae 5 1 4 41 8 33
Deaths:
Hib pneumonia 1 0 1 120 24 95
Hib meningitis 1 0 1 207 42 165
Hib NPNM 1 0 1 92 19 74
DALYs 187 35 152 14,382 2,909 11,473
No. of outpatient visits 1,903 357 1,546 5,122 1,040 4,082
No. of hospital admissions 647 121 525 2,561 520 2,041
Outpatient visit costs (US$):
Hib pneumonia 14,082 2,644 11,438 6,231 1,265 4,966
Hib meningitis 2,883 541 2,342 1,023 208 816
Hib NPNM 752 141 611 583 118 465
Inpatient admission costs (US$):
Hib pneumonia 223,195 41,907 181,288 397,055 80,598 316,457
Hib meningitis 86,705 16,280 70,425 110,921 22,516 88,405
Hib NPNM 20,220 3,796 16,423 63,172 12,823 50,348
Meningtis sequelae costs (US$) 75,261 14,048 61,213 905,085 182,861 722,224
doi:10.1371/journal.pone.0021472.t003
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Government. Each year, the Uzbek Government saves approxi-
mately US$ 6.18 million; 5 million for vaccines and syringes
donated by GAVI and 1.18 million in treatment costs averted.
Sensitivity analysis
When using the GBD EURO parameter values for incidence
and CFRs the vaccine becomes considerably more cost-effective
in Belarus while there are only marginal differences in the
Uzbekistan results (Table 5). Since the CFR for meningitis in the
GBD EURO estimates is 27%, while we assumed 3.2% in the
base case for Belarus, considerably more deaths are averted in
the GBD scenario, increasing the cost-effectiveness of the
vaccine. Increased access to care in Uzbekistan makes the
vaccine less cost-effective as fewer deaths would be averted
(Figure 2). In contrast, a reduction in the vaccine price to US$
2.00 per dose would improve the cost-effectiveness markedly in
both countries.
Discussion
Our analysis demonstrated that the ICER is considerably less in
Uzbekistan than in Belarus. The most important reason for this
difference is that the baseline Hib mortality burden, expressed as
case fatality rates, is higher in Uzbekistan than in Belarus, leading
to more deaths averted per child vaccinated. Table 6 provides a
comparison of key indicators on the two countries. It is seen that
the less than five mortality rate is 17 times higher in Uzbekistan
than in Belarus and that the proportion due to pneumonia is
approximately 21% in Uzbekistan while only 4% in Belarus.
Hence, Hib vaccine will prevent proportionally more deaths in
Uzbekistan than in Belarus and since mortality is the most
important driver of DALYs, the ICER becomes more favourable
in Uzbekistan.
Other, albeit less important, explanations for the ICER
difference are that the vaccine price is higher in Belarus than in
Table 4. Vaccine and syringe costs with and without Hib vaccine (2010 US$).
Belarus Uzbekistan
Antigen
Doses in
schedule Vaccine costs
Injection
supplies Total
Doses in
schedule
Vaccine
costs
Injection
supplies Total
BCG 1 14,231 9,572 23,802 1 49,928 56,931 106,859
Hepatitis B 3 184,284 26,049 210,333 4 694,253 189,769 884,023
DTP 4 63,945 34,732 98,677 4 588,462 189,769 778,232
MMR 1 245,634 12,060 257,694 1 1,121,184 54,523 1,175,707
OPV 2 72,178 - 72,178 5 1,264,578 - 1,264,578
IPV 3 1,402,315 26,049 1,428,364 0 - - -
Total without Hib vaccine 1,982,586 108,462 2,091,049 3,718,406 490,993 4,209,399
Costs per child w/o Hib vaccine 21.85 1.20 23.04 7.05 0.93 7.98
Hib combination vaccine* 4 1,814,760 48,239 1,862,999 3 5,345,975 142,327 5,488,302
Total with Hib vaccine** 3,733,401 121,969 3,855,371 8,102,345 348,666 8,451,011
Costs per child with Hib vaccine 41.14 1.34 42.48 15.36 0.66 16.02
Incremental costs 1,750,815 13,507 1,764,322 4,383,938 2142,327 4,241,611
*DTP-Hib in Belarus and DTP-HepB-Hib in Uzbekistan.
**In Uzbekistan, hepatitis B vaccine birth dose and booster dose of DTP at 18 months are included here.
doi:10.1371/journal.pone.0021472.t004
Table 5. Incremental cost-effectiveness of Hib vaccine for the 2009 birth cohort in Belarus and Uzbekistan: Base case analysis and
alternative scenario using GBD EURO estimates (discounted values).
Base case With GBD EURO estimates*
Belarus Uzbekistan Belarus Uzbekistan
Annual incremental vaccine costs (US$) 1,764,322 4,241,611 1,764,322 4,241,611
Treatment costs averted (US$) 343,740 1,183,681 676,114 1,676,923
Annual net costs (US$) 1,420,582 3,057,930 1,088,208 2,564,688
Hib disease cases averted 467 3,002 1,081 6,373
Hib deaths averted 3 334 66 388
Hib meningitis sequelae cases averted 4 33 3 36
DALYs averted 152 11,473 2,316 13,313
Incremental costs per death averted (US$) 485,567 9,162 16,514 6,606
Incremental costs per DALY averted (US$) 9,323 267 470 193
*Global Burden of Disease incidence and case fatality rates for the WHO European region [6].
doi:10.1371/journal.pone.0021472.t005
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Uzbekistan and that Belarus uses a four-dose schedule while only
three doses are used in Uzbekistan. Incremental vaccine costs per
child are consequently US$ 21.17 in Belarus and only US$ 7.0 in
Uzbekistan. A booster dose is recommended in countries where
Hib disease is a substantial problem in children above 12 months
[35]. In the Minsk city meningitis surveillance it was found that as
many as 80% of Hib cases were above 12 months; confirming the
need for a booster dose. While there is no age-specific data on Hib
disease available from Uzbekistan, the requirement for a booster
dose might be less in this country. In a review of Hib disease age
distributions, Bennett et al. found that while 60% of cases were
above 12 months in the WHO European, the average was only
20% in the WHO South East Asian region [36]. It is thus possible
that a similar impact is achieved in Uzbekistan with three doses as
with four doses in Belarus, but this hypothesis can only be
confirmed by undertaking intensive Hib disease surveillance.
When deciding whether Hib vaccine is a good use of scarce
resources, the ICER values need to be viewed in relation to ability
and willingness to pay for health care. The 2009 Gross Domestic
Products (GDP) per capita was US$ 5,560 in Belarus and US$
1,100 in Uzbekistan[37]. Hence, in relative terms, the Belarus
Government is able to pay considerably more per DALY averted
than the Uzbekistan Government. According to WHO recom-
mendations, interventions that cost less than GDP per capita
should be considered highly cost-effective and those that cost
between one and three times GDP per capita cost-effective[38].
Hence, with these thresholds Hib vaccine can be considered highly
cost-effective in Uzbekistan and cost-effective in Belarus. While
economic evaluations of other interventions are limited in the two
countries, a study on rotavirus vaccine in Uzbekistan was
published in 2007[39]. At a rotavirus vaccine price of US$ 5 per
course, it was estimated that the costs per discounted DALY
averted amount to between US$ 75 and US$ 242; values
comparable with our findings for Hib vaccine.
Our results are in a similar range with other economic
evaluations of Hib vaccine. In a systematic review it was found
that, in 2008 values, the costs per discounted DALY averted
amounted to US$ 42 in Kenya, US$ 69 in Indonesia and US$
10,842 in Moscow [40]. The favourable cost-effectiveness ratios in
Kenya and Indonesia can be attributed to higher infant mortality
and Hib disease incidence rates in these parts of the world than
seen in Eastern Europe and Central Asia [6]. Economic
evaluations of Hib vaccine in high-income countries include
studies from France [41], Sweden [42,43] and the USA [44]. In
the French study, the costs per discounted Quality Adjusted Life
Year gained amounted to US$ 8,054, which is comparable to our
result from Belarus. In the Swedish and the US studies a cost-
benefit approach involving attaching a monetary value to life years
lost to death and disability were used and it was concluded that the
vaccine is cost saving in both countries.
The main limitation of our study is relatively large uncertainty
in the disease-specific parameter values, in particular for
pneumonia. This is a limitation faced by all researchers working
within the field of invasive bacterial diseases in countries with
Figure 2. Scenario analysis. Impact on discounted costs per DALY averted from univariate changes in parameter values.
doi:10.1371/journal.pone.0021472.g002
Table 6. Comparison of key indicators and study results between the two countries.
Indicator Belarus Uzbekistan Source
2009 GDP per capita US$ 5,560 US$ 1,100 [37]
Hospital beds per 1,000 population 11 5 [45]
2008 mortality rate per 100,000 children , 5 years 1,245 21,200 [46]
Percent of deaths due to pneumonia in children , 5 years 4% 21% [46]
Percent of deaths in children , 5 years prevented from Hib vaccine 0.28% 1.1% Present analysis
Incremental costs of Hib vaccine introduction per fully vaccinated child US$ 19.44 US$ 8.04 Present analysis
Incremental costs per discounted DALY averted US$ 9,323 US$ 267 Present analysis
doi:10.1371/journal.pone.0021472.t006
Economic Evaluation of Hib Vaccination
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21472
laboratory resource constraints. In many settings, the true
incidence of Hib disease remains largely unknown because the
signs and symptoms are difficult to differentiate from those caused
by other microorganisms, such as Streptococcus pneumoniae, viruses
and parasites. Indeed, the true contribution from a particular
bacterium can only be determined from high-quality laboratories,
but these are still lacking in many places. Moreover, even in
settings with adequate laboratory services, widespread use of
antibiotics before hospitalization is an important constraint to
detection as this hinders growth of the bacteria. Finally, in many
low-income countries, children with the highest disease burden
have poor access to care and many die before they reach hospital.
We adjusted for this factor in Uzbekistan, but since the exact value
of this proportion is very difficult to determine, this parameter is
one of the most uncertain in our analysis.
An additional limitation is the use of a static model that does not
reflect the change in the force of infection over time. However,
data needed for a dynamic model, such as age-specific carriage
rates and population mixing are not readily available from the two
countries. We incorporated possible herd immunity effects in a
crude manner in the scenario analysis, but this prediction can only
be considered a best guess. However, it could be argued that from
a policy perspective there is limited additional benefit of a dynamic
analysis when a static model, which takes a conservative approach,
already demonstrates cost-effectiveness.
To increase the strength of our analysis, we prioritised data from
national surveillance systems, even if more reliable values might be
available from large-scale epidemiological studies in other
countries. Our analysis is thus an example of how to undertake
an economic evaluation with data gathered from routine data
sources while using results from other countries only as a quality
marker. Undertaking the analysis for two countries simultaneously
brings several advantages as useful comparisons can be made on
both parameter values and the overall results. When assessing the
marked differences in terms of costs per discounted DALY averted
between the two countries, valuable insights into the most
important drivers of the results were made. Moreover, a key
limitation frequently stated regarding economic evaluation studies
is that they cannot easily be compared because of differences in
methodologies. We facilitated such a comparison by using the
same decision-analytic model for the two countries.
While data on Hib disease burden from Eastern Europe and
Central Asia remain scarce, we have illustrated that the vaccine
can be considered cost-effective despite conservative assumptions
about incidence and mortality. However, international cost-
effectiveness thresholds say nothing about affordability, and with
increases in vaccine costs of 84% and 101%, respectively, both
Governments should consider carefully the long-term financial
sustainability. The GAVI Alliance is currently increasing its
support for pneumococcal and rotavirus vaccine introductions and
it is likely that its support to Hib vaccine will stop when the current
five year commitments come to an end. In countries with relatively
high under-five mortality, such as Uzbekistan, Hib vaccine is a
highly cost-effective intervention and it is therefore vital that the
future financial sustainability of the vaccine is secured.
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